EICHORCondition: Interstitial Lung Diseases · Sponsor: Boehringer Ingelheim
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression. Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check parti…
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| Newport Native MD, Inc | Newport Beach, California, United States | — |
| Clinical Research Specialists LLC - Kissimmee | Kissimmee, Florida, United States | — |
| Lakeland Regional Medical Center - Lakeland | Lakeland, Florida, United States | — |
| Advanced Pulmonary Research Institute | Loxahatchee Groves, Florida, United States | — |
| Avanza Medical Research Center | Pensacola, Florida, United States | — |
| Coastal Pulmonary & Critical Care | St. Petersburg, Florida, United States | — |
| Indiana University Health Enterprise Clinical Research Operation | Indianapolis, Indiana, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| University of Minnesota | Minneapolis, Minnesota, United States | — |
+ 139 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07540988